A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
LUPUS ANTICOAGULANT REFLEXIVE PANEL
MessageRequires platelet-poor plasma; see Additional Information below for instruction.
Test Code
LUPS1
CPT Codes
85610; 85730; 85520; 85670, if reflexed 85384; If results for all 4 tests above are normal, then: 85613 (up to x3); 85730 (up to x3)
Includes
Panel components: PT, PTT, Thrombin Time, Anti-Xa, Fibrinogen (if indicated), dRVVT and Silica Clotting Time Screen (SCT), dRVVT and SCT confirmation (if indicated), dRVVT and SCT mixing studies (if indicated) and Pathologist interpretation.
Preferred Specimen
2 Blue tubes (Sodium Citrate)
Requires platelet-poor plasma; see Additional Information below for instruction.
Requires platelet-poor plasma; see Additional Information below for instruction.
Minimum Volume
1 mL platelet-poor plasma
See Additional Information below for instruction.
See Additional Information below for instruction.
Other Acceptable Specimens
None
Instructions
Tube MUST be full for proper whole blood to anticoagulant ratio. Invert tube "end-to-end" to prevent clotting. Centrifuge to obtain platelet-poor plasma. See Additional Information below for obtaining a platelet-poor sample.
Transport Container
Stanfard transfer tube
Transport Temperature
Frozen
Specimen Stability
Frozen at -20°C or lower up to 14 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
The following conditions will be rejected:
- Refrigerated plasma samples that are >4 hours from collection
- Clotted samples
- Grossly hemolyzed samples
Methodology
Clot Detection
Setup Schedule
M, W, F only
Report Available
Within 24 hours of day tested at the performing laboratory.
Reference Range
Component | Reference Range |
---|---|
PT | 10.1 - 13.1 sec |
PTT | 25.0 - 36.0 sec |
Thrombin Time | 10.3 - 16.6 sec |
Anti-Xa | Not Present |
Fibrinogen (if indicated) | 163 - 463 mg/dL |
dRVVT Screen Ratio | <1.20 |
Silica Clotting Time Screen Ratio (SCT) | <1.22 |
dRVVT Confirmation Total Ratio (if indicated) | <1.20 |
Silica Clotting Time Confirmation (SCT) Total Ratio (if indicated) | <1.22 |
dRVVT Screen Mixing Study Ratio (if indicated) | <1.20 |
Silica Clotting Time Confirmation (SCT) Screen Mixing Study Ratio (if indicated) | <1.22 |
Clinical Significance
Use for unexplained prolonged PTT or for patients with a significant probability of having antiphospholipid syndrome (APS).
Performed By
Alverno Laboratories
Performing Laboratory
Alverno Central Lab
NHMC (Hematology, IL Coag)
Additional Information
Obtaining A Platelet-Poor Specimen
Last Updated: August 2, 2024